ALT Pemvidutide Cuts AUD Heavy Drinking in Phase 2

Altimmune (NASDAQ: ALT) reported positive topline results from the RECLAIM Phase 2 trial on July 28, showing its dual GLP-1/glucagon agonist pemvidutide significantly reduced heavy drinking in patients with alcohol use disorder (AUD). It is the first Phase 2 evidence that a GLP-1-class drug can treat addiction, extending the weight-loss drug class into a new therapeutic area.

Pemvidutide (2.4 mg weekly) cut heavy drinking days by 4.20 per week versus 2.75 for placebo (LS mean difference -1.45, p=0.0014), meeting the primary endpoint. Every secondary endpoint was positive: 64.4% of treated patients achieved a two-level reduction in WHO Risk Drinking Levels versus 34.8% on placebo (OR 3.31, p=0.0049), and 42.2% reported zero heavy drinking days in the final four weeks versus 17.4% for placebo.

The blood biomarker data is the hard evidence. PEth, a direct measure of alcohol consumption in red blood cells, dropped 153.4 points in the pemvidutide arm versus a 22-point increase in placebo (p<0.0001). That is a 38% reduction in measured alcohol intake for treated patients against a 5.9% rise for placebo. Blood biomarkers matter because self-reported drinking data is notoriously unreliable; PEth confirms patients actually drank less, not just said they did.

RECLAIM enrolled approximately 100 patients with AUD and BMI above 25, randomized 1:1 to pemvidutide or placebo over 24 weeks (NCT06987513). Safety was consistent with the GLP-1 class profile: nausea (44% vs 24% placebo), vomiting (18% vs 6%), and constipation (26% vs 6%), mostly mild to moderate. Treatment discontinuations were 20% for pemvidutide versus 22% for placebo.

Altimmune closed at $2.99 on July 28, down $0.17 from the prior session, with a market cap of approximately $576 million. The stock barely moved on the news, reflecting investor focus on pemvidutide’s Phase 3 MASH program (PERFORMA, initiating H2 2026) rather than the AUD indication, which is years from an NDA filing. An End-of-Phase 2 meeting with the FDA is planned for AUD.

Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist. The glucagon receptor component targets liver fat, inflammation, and fibrosis directly, while the GLP-1 component mediates appetite suppression and weight loss and may modulate reward pathways tied to craving. That dual mechanism is why the same drug is in Phase 3 for MASH and now shows efficacy in AUD, two conditions linked by liver pathology.

The competitive context for AUD is thin. Only three FDA-approved drugs exist: naltrexone (1994), acamprosate (2004), and disulfiram, all decades old with modest efficacy. Fewer than 2% of the estimated 28 million US adults with AUD use any of them. A GLP-1-class drug with objective biomarker validation would be a new option in a field that has not seen innovation in over 20 years. The same liver pathology connects AUD to MASH, where Madrigal’s Rezdiffra became the first approved drug and where pemvidutide is heading to Phase 3.

The risk is execution capacity. Altimmune is a microcap preparing a Phase 3 MASH trial while running the RESTORE Phase 2 in alcohol-associated liver disease and now pursuing AUD on top. Running two registrational-track programs simultaneously on a $576 million market cap is capital-intensive. The company reported $535 million in cash at the end of Q1 2026, enough to start PERFORMA but not enough to fund three programs to completion without a partner or dilution.

What to watch next: the End-of-Phase 2 meeting with the FDA for AUD, where the registrational path will be defined. The RECLAIM data is strong enough to support a Phase 3 program, but Altimmune must decide whether AUD is a priority or a strategic option that waits behind MASH.

What It Means for the Trade

The flat close on a readout this clean tells you where the stock’s risk actually sits: the market values Altimmune on MASH PERFORMA (Phase 3, initiating H2 2026), not on a second indication that is years from filing. That is rational — but it also means the market may be mispricing what RECLAIM just did to the platform. A single molecule showing statistically significant efficacy in both MASH and AUD is evidence that the glucagon component is doing real pharmacological work across reward and liver pathology, not just generating weight loss. That matters for PERFORMA underwriting: the mechanism story just got independently corroborated in a different organ system, which is more than most dual-agonist programs can show at this stage.

The strategic decision the stock is not pricing: whether AUD becomes a funded registrational program or a partnered one. Alcohol use disorder is a market the GLP-1 class is circling — Lilly and Novo are running or have run addiction-adjacent trials with their own incretins — and RECLAIM’s biomarker-validated data makes pemvidutide one of the most advanced assets in the space. An AUD partnership before the End-of-Phase 2 meeting would validate the indication without diluting MASH economics; self-funding it strains a balance sheet that already has to carry PERFORMA. Watch the End-of-Phase 2 meeting outcome and any partnership language around it — that is the next tell on how the company sizes the opportunity.

Mechanism and Market Context

Why a weight-loss drug works on drinking: GLP-1 receptors are expressed in brain reward circuitry, and incretin signaling modulates the mesolimbic dopamine pathways that reinforce alcohol seeking. The clinical literature on GLP-1 agonists and alcohol craving had been building from small trials before RECLAIM; this is the first Phase 2 with a dedicated primary endpoint and a biomarker backbone. The PEth data is what makes the readout credible where self-report-only addiction trials are not: a 153.4-point PEth drop versus a 22-point placebo increase (p<0.0001) is objective exposure evidence, and the 42.2% heavy-drinking-day abstinence rate in the final four weeks versus 17.4% on placebo is the kind of responder fraction that translates into registrational trial design.

The market framing is the uncomfortable part. Only three drugs are FDA-approved for AUD — naltrexone, acamprosate, disulfiram — all decades old, all modestly effective, and fewer than 2% of the estimated 28 million U.S. adults with AUD use any of them. That is either a massive untapped market or a commercial graveyard, and the history of CNS-addiction drug launches argues for caution: the untreated population is untreated partly because the delivery system (primary care screening, addiction medicine infrastructure) does not exist at scale. A GLP-1-class drug riding existing metabolic-prescribing infrastructure could change that — the same cardiometabolic physicians already writing incretin prescriptions are the ones seeing AUD comorbidity in their patients — but that is a thesis, not data.

Risks and What Could Go Wrong

1. Capital allocation: $535 million in cash against a Phase 3 MASH program, a Phase 2 in alcohol-associated liver disease (RESTORE), and a prospective AUD Phase 3 is a stretch. Dilution or a deal that undervalues one of the programs is the base-case risk, not the science.
2. PERFORMA is the valuation driver, and nothing in RECLAIM de-risks it. A MASH trial miss drops the stock regardless of AUD’s promise.
3. The addiction-medicine commercialization question has no validated answer — payer coverage for AUD pharmacotherapy is thin, and off-label GLP-1 use for drinking could cannibalize the regulated market before pemvidutide ever files.
4. Larger incretin players (Lilly, Novo) with deeper addiction programs could leapfrog pemvidutide’s head start with semaglutide or tirzepatide data in AUD.

Position read: ALT at a $576 million market cap is a MASH call option with AUD stapled to it for free. The RECLAIM data raised the option’s value; it did not change the primary bet. Size for PERFORMA, enjoy the AUD kicker if it monetizes.